Read the latest ideas, insights and observations on the Australian Medicinal Cannabis Industry from the team at FreshLeaf Analytics.
FreshLeaf Analytics has released a comprehensive report on the current status of the Australian medicinal cannabis market. The FreshLeaf H1 2021 product, pricing and patient analysis report found
An industry report has warned Australia risks losing a billion dollar industry. Australia risks losing a billion dollar industry if medicinal cannabis is not correctly
You no longer need a prescription to get low-dose cannabidiol, though it’ll be months before approved products hit the shelves. And no, you can’t get
Cannabis oil firms chase approvals as over-the-counter sales are legalised Low dose cannabis oil can be bought over the counter at pharmacies from Monday for
Score check: Here’s how ASX pot stocks have responded to the US Senate result As ever, US politics is full of surprises — and ASX
From early 2021 you’ll technically be allowed to buy low-dose cannabis oil from pharmacies without a prescription. However, while the laws have been changed so
Therapeutic Goods Administration (TGA) makes final ruling on over-the-counter low-dose CBD, firing the starting gun for companies in race to bring products to market, increasing
Unregistered Cannabis Products Fail to Meet TGA Requirements 22nd September, 2020 The TGA’s recent Laboratories Testing Report on routine surveillance of unregistered products supplied to
Australia’s Most Comprehensive Medicinal Cannabis Report: Q3 2020 Thursday 17 September 2020 FreshLeaf Analytics is excited to release Australia’s most comprehensive medicinal cannabis Patient, Product
Green Fund: Australian Government Legalizes Over-The-Counter CBD
Cannabiz: Major doubts remain as industry reacts to CBD down scheduling
Stockhead Cannabis stocks were one of the rare groups in the green on a dismal day for the ASX on Wednesday following an interim ruling by the
© 2021 All rights reserved, FreshLeaf Analytics
